In this episode of EASL Studio, a very special interview with Prof. Stephan Urban talking about his journey of the discovery and development of the first HBV/HDV entry inhibitor.

  • Where did the story begin and what were the major breakthroughs and challenges?
  • What are the mechanisms of viral entry inhibitors and how it differs from direct acting antivirals mode of action?
  • How does it impact the future of HBV/HDV treatment landscape?

This project has been made possible with the provision of a financial grant from Gilead Sciences Europe Ltd.
EASL has received no input from Gilead with regard to the content of this programme.

ℹ️ Please click here to access the podcast version of this EASL Studio episode.



Stephan Urban Professor Stephan Urban is head of the Translational Virology unit at the Department of Infectious Diseases, Molecular Virology at Heidelberg University. Between 2008 and 2012 he was Project coordinator of the BMBF-network “Innovative Therapies” and is now coordinating the Hepatitis D project within the German Centre of Infection Research (DZIF). He has published in numerous peer reviewed journals on Hepatitis B, C and D. He is the recipient of the Pettenkofer Price of the Pettenkofer Foundation. In 2014 he was awarded with the 1. DZIF Research Award. In 2021, he received the The Distinguished Award in Hepatitis B Research.
Thomas Berg

Professor Dr. Thomas Berg is Head of the Division of Hepatology, Department of Medicine II, at the Leipzig University Medical Center, Germany, and Chair of the University Liver Tumor Center, and Vice-Chair of the University Liver Transplant Center Leipzig. He is Secretary General of the European Associations for the Study of the Liver (EASL), Board member of the EASL International Liver Foundation (EILF) and served the Journal of Hepatology as Co-Editor between 2014 and 2019. He has published more than 440 articles in peer-reviewed journals and more than 100 reviews and textbook contributions. His h-index is 76 (Scopus).